A retrospective comparison of allogeneic peripheral blood stem cell and bone marrow transplantation results from a single center: A focus on the incidence of graft-vs.-host disease and relapse

To detect the effect of the stem cell source, allogeneic peripheral blood stem cell transplantations (alloPBSCTs) performed between 1995 and 1997 from human leukocyte antigen (HLA)-identical siblings in 40 patients with acute and chronic hematological disorders were compared with a historical group of 40 patients with similar variables who had received allogeneic bone marrow transplants (alloBMTs) between 1993 and 1995. Patients in both groups were identical except that both the recipient and the donor ages were, on average, higher in the alloPBSCT group (26 vs. 36 [p = 0.005] and 27 vs. 32 [p = 0.024], respectively). Patients received similar therapy excluding posttransplant granulocyte colony-stimulating factor administration (97% in alloBMT vs. 12.5% in alloPBSCT). The median time to reach neutrophil counts >0.5×109/L and platelet counts >20×109/L was 13 and 14 days, respectively, in patients receiving alloPBSCTs compared with 19 and 27 days in patients receiving alloBMTs (p = 0.0014 and p = 0.0002). The alloPBSCT group required similar transfusions of red blood cells or platelets. The incidence of grade II-IV acute graft-vs.-host disease (aGVHD) was similar in both groups. However, chronic GVHD (cGVHD) of all grades developed in 78.1% of patients in the alloPBSCT group after a median follow-up period of 12.5 (range 0.5-34) months. In alloBMT recipients, cGVHD of all grades developed in 21.4% after a median follow-up period of 38 (range 0.5-62) months (p = 0.00001). Day 100 transplant-related mortality was also similar: 20% (8 of 40) in the alloBMT patients and 17.5% (7 of 40) in the alloPBSCT group. Although not statistically significant, a relatively higher relapse rate occurred in the alloBMT group (21.4 vs. 10.7%). The estimated disease-free survival in month 24 was 51.3% for alloBMT and 54.6% for alloPBSCT, and the estimated overall survival in month 24 was 56.1% for alloBMT and 64.6% for alloPBSCT. In conclusion, this retrospective comparison suggests that alloPBSCT from HLA-identical donors is associated with faster engraftment, fewer transfusions, and no greater incidence of aGVHD, but a high incidence of cGVHD

Phase 2 study of dovitinib in patients with relapsed or refractory multiple myeloma with or without t(4;14) translocation

Objectives: Approximately 15% of patients with multiple myeloma (MM) exhibit a t(4;14) translocation, which often results in constitutive activation of the receptor tyrosine kinase (RTK) fibroblast growth factor receptor 3 (FGFR3). This study evaluated the efficacy and safety of dovitinib, an RTK inhibitor with in vitro inhibitory activity against FGFR, in patients with r

Retrospective matched-pairs analysis of bortezomib plus dexamethasone versus bortezomib monotherapy in relapsed multiple myeloma

Bortezomib-dexamethasone is widely used for relapsed myeloma in routine clinical practice, but comparative data versus single-agent bortezomib are lacking. This retrospective analysis compared second-line treatment with bortezomib- dexamethasone and bortezomib using 109 propensity score-matched pairs of patients treated in three clinical trials: MMY-2045, APEX, and DOXIL-MMY-3001. Propensity scores were estimated using logistic regression analyses incorporating 13 clinical variables related to drug exposure or clinical outcome. Patients received intravenous bortezomib 1.3 mg/m2 on days 1, 4, 8, and 11, in 21-day cycles, alone or with oral dexamethasone 20 mg on the days of/after bortezomib dosing. Median bortezomib cumulative dose (27.02 and 28.60 mg/m2) and treatment duration (19.6 and 17.6 weeks) were similar with bortezomib-dexamethasone and bortezomib, respectively. The overall response rate was higher (75% vs. 41%; odds ratio=3.467; P<0.001), and median time-to-progression (13.6 vs. 7.0 months; hazard ratio [HR]=0.394; P=0.003) and progression-free survival (11.9 vs. 6.4 months; HR=0.595; P=0.051) were longer with bortezomib-dexamethasone versus bortezomib, respectively. Rates of anygrade adverse events, most common grade 3 or higher adverse events, and discontinuations due to adverse events appeared similar between the groups. Two patients per group died of treatment-related adverse events. These data indicate the potential benefit of bortezomib-dexamethasone compared with single-agent bortezomib at first relapse in myeloma. The MMY-2045, APEX, and DOXIL-MMY-3001 clinical trials were registered at, respectively, clinicaltrials.gov identifier: 00908232, 00048230, and 00103506

Prevention and management of adverse events of novel agents in multiple myeloma: A consensus of the European Myeloma Network

During the last few years, several new drugs have been introduced for treatment of patients with multiple myeloma, which have significantly improved the treatment outcome. All of these novel substances differ at least in part in their mode of action from similar drugs of the same drug class, or are representatives of new drug classes, and as such present with very specific side effect profiles. In this review, we summarize these adverse events, provide information on their prevention, and give practical guidance for monitoring of patients and for management of adverse events

Factors Influencing The Success Of Cord Blood Collection: A Tertiary Perinatal Medicine Center’S Experience

ScopusWo

Amniotic Fluid β2- Microglobulin Measurements

OBJECTIVE: To determine β2-microglobulin levels in amniotic fluid during the course of second trimester. STUDY DESIGN: One hundred patient’s amniotic fluid β2-microglobulin levels had been evaluated retrospectively (March-October 2009). The most common amniocentesis indication was advanced maternal age (33.3%). Others were; high risk result for triple test (18.5%), high risk result for double test (6.48%), ventriculomegaly (5.55%), obstetric history for fetus with down syndrome (4.62%), the presence of soft markers on ultrasound (13.8%), others (17.8%). Patients average gravida was 2.66 (range: 1-6), parity was 0.75 (range: 0-3), abortion was 0.65 (range: 0-3). RESULTS: All patients were at second trimester and the average gestational week was 17.7 (range 15- 22). Patients were divided into four groups (15th, 16th, 17-18th and 19-20th gestational weeks). We have demonstrated that amniotic fluid β2-microglobulin levels are increased progressively throughout the second trimester. We have specified normal β2-microglobulin values of each gestational week/period in order to be used in clinical practice. CONCLUSION: We have demonstrated that amnionic fluid β2-microglobulin levels are increased progressively throughout the second trimester

Total Blood Lymphocyte Count Alteration During and after Pregnancy

Objective: To investigate the impact of gestational changes on blood lymphocyte count in healthy pregnancies. Study Design: This retrospective study is consisted of 108 consecutive normal pregnancies who delivered at our department in December 2015. High-risk pregnancies with poor neonatal outcome and pregnancies with maternal disorders which may affect lymphocyte counts were excluded from the study. “Complete blood count” results of the patients were obtained from the computerized data base system of Hacettepe University Hospital. Blood samples of patients which were withdrawn a) prior to pregnancy (1-6 months before getting pregnant), b) during pregnancy (11-14th gestational weeks) and c) post-partum first day were used in this study. Results: The mean blood lymphocyte count was 2049.07 (±758.69) in patients before their pregnancies. The mean lymphocyte count decreased to 1850.93 and 1625 during pregnancy and after delivery respectively. A statistically significant decrease was found between three periods (before, during, and postpartum 1st day) (p:0.003). Conclusion: We have shown a significant decrease in total lymphocyte levels during pregnancy, consistent with the data presented in the literature. Pregnancy and related hormones have a negative impact on total blood lymphocyte level

Pregnancy after Cancer Treatment and Pregnancy Associated Cancer: A Single Center Experience with 96 Cases

OBJECTIVE: The objective of our study was to evaluate our experience on pregnancies after cancer treatment and pregnancy-associated cancer. STUDY DESIGN: The clinical records of 96 pregnant women including previously received treatment for cancer and association of cancer with pregnancy who admitted to our department were enrolled between 2002 and 2012. Demographics, pregnancy outcomes, maternal and fetal complications, perinatal outcomes, cancer types and treatments performed were evaluated. RESULTS: The study group was consisting of 96 cases, 59 out of 96 were cancer survivors and 37 were pregnancy-associated cancer patients. Of those thirty seven, 25 were synchronous with the pregnancy and 12 were metachronic. Pregnancies resulted in 77 healthy newborns, 7 abortions and 12 medical terminations. The most common type of cancer was the breast cancer in 25 patients, followed by thyroid, leukemia, osteosarcoma, lymphoma and ovarian cancer. Patients were treated for their cancer with different modalities including surgery, chemotherapy and radiotherapy. We encountered maternal mortality in 8 cases, all occurred after delivery. CONCLUSIONS: Since management of a pregnancy of a cancer survivor and pregnant woman with cancer a hard work, multidisciplinary approach involving gynecologists, pediatricians, oncologists is essential. Interval between cancer and pregnancy and timing of initiation of therapy in cases of pregnancy associated cancer are important issues in the perspective of fetal/neonatal well-being